PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23826175-0 2013 Fish oil and the pan-PPAR agonist tetradecylthioacetic acid affect the amino acid and carnitine metabolism in rats. Carnitine 86-95 peroxisome proliferator activated receptor alpha Rattus norvegicus 21-25 25012467-1 2014 BACKGROUND: Activation of peroxisome proliferator-activated receptor (PPAR)alpha and PPARdelta causes an elevation of tissue carnitine concentrations through induction of genes involved in carnitine uptake [novel organic cation transporter 2, (OCTN2)], and carnitine biosynthesis [gamma-butyrobetaine dioxygenase (BBD), 4-N-trimethyl-aminobutyraldehyde dehydrogenase (TMABA-DH)]. Carnitine 125-134 peroxisome proliferator activated receptor alpha Rattus norvegicus 70-80 25012467-1 2014 BACKGROUND: Activation of peroxisome proliferator-activated receptor (PPAR)alpha and PPARdelta causes an elevation of tissue carnitine concentrations through induction of genes involved in carnitine uptake [novel organic cation transporter 2, (OCTN2)], and carnitine biosynthesis [gamma-butyrobetaine dioxygenase (BBD), 4-N-trimethyl-aminobutyraldehyde dehydrogenase (TMABA-DH)]. Carnitine 189-198 peroxisome proliferator activated receptor alpha Rattus norvegicus 70-80 25012467-2 2014 Recent studies showed that administration of the plasma lipid-lowering drug niacin causes activation of PPARalpha and/or PPARdelta in tissues of obese Zucker rats, which have a compromised carnitine status and an impaired fatty acid oxidation capacity. Carnitine 189-198 peroxisome proliferator activated receptor alpha Rattus norvegicus 104-113 25012467-3 2014 Thus, we hypothesized that niacin administration to obese Zucker rats is also able to improve the diminished carnitine status of obese Zucker rats through PPAR-mediated stimulation of genes involved in carnitine uptake and biosynthesis. Carnitine 202-211 peroxisome proliferator activated receptor alpha Rattus norvegicus 155-159 25012467-8 2014 We assume that the induction of genes involved in carnitine uptake and biosynthesis by niacin administration is mediated by PPAR-activation. Carnitine 50-59 peroxisome proliferator activated receptor alpha Rattus norvegicus 124-128 21169901-0 2011 Carnitine regulates myocardial metabolism by Peroxisome Proliferator-Activated Receptor-alpha (PPARalpha) in alcoholic cardiomyopathy. Carnitine 0-9 peroxisome proliferator activated receptor alpha Rattus norvegicus 45-93 19552975-11 2011 Furthermore, blockade the potential PGI(2) receptors, including PGI(2) receptors (IP receptors), and peroxisome proliferator-activated receptors alpha and delta (PPARalpha and PPARdelta), revealed that the siRNA-mediated blockage of PPARalpha considerably reduced the anti-apoptotic effect of L-carnitine. Carnitine 293-304 peroxisome proliferator activated receptor alpha Rattus norvegicus 233-242 19552975-12 2011 CONCLUSIONS: These findings suggest that L-carnitine protects cardiomyocytes from doxorubicin-induced apoptosis in part through PGI(2) and PPARalpha-signaling pathways, which may potentially protect the heart from the severe toxicity of doxorubicin. Carnitine 41-52 peroxisome proliferator activated receptor alpha Rattus norvegicus 139-148 21169901-0 2011 Carnitine regulates myocardial metabolism by Peroxisome Proliferator-Activated Receptor-alpha (PPARalpha) in alcoholic cardiomyopathy. Carnitine 0-9 peroxisome proliferator activated receptor alpha Rattus norvegicus 95-104 21169901-16 2011 Carnitine may improve myocardial metabolism by elevating the content of PPARalpha, CPT-I and MCAD. Carnitine 0-9 peroxisome proliferator activated receptor alpha Rattus norvegicus 72-81 19154956-0 2009 Peroxisome proliferator-activated receptor alpha and enzymes of carnitine biosynthesis in the liver are down-regulated during lactation in rats. Carnitine 64-73 peroxisome proliferator activated receptor alpha Rattus norvegicus 0-48 19447019-8 2010 Furthermore, blockading potential PGI(2) receptors, including immunoprecipitation (IP) receptors and peroxisome proliferator-activated receptors alpha (PPAR alpha) and delta, revealed that siRNA-mediated blockage of PPAR alpha considerably reduced the anti-proliferation effect of L-carnitine. Carnitine 281-292 peroxisome proliferator activated receptor alpha Rattus norvegicus 216-226 19447019-9 2010 In summary, these results suggest that L-carnitine attenuates Ang II-induced effects (including NADPH oxidase activation, sphingosine-1-phosphate generation and cell proliferation) in part through PGI(2) and PPAR alpha-signaling pathways. Carnitine 39-50 peroxisome proliferator activated receptor alpha Rattus norvegicus 208-218 19791468-9 2009 CONCLUSION: PPARalpha and RXRalpha downregulation is significantly correlated with cardiac dysfunction in this alcoholic cardiomyopathy model, carnitine ameliorated the cardiac fibrosis and remodeling possibly through upregulating the metabolic pathways of PPARalpha and RXRalpha. Carnitine 143-152 peroxisome proliferator activated receptor alpha Rattus norvegicus 257-266 19154956-6 2009 In conclusion, the present study demonstrates for the first time that lactation leads to a down-regulation of PPARalpha and genes involved in hepatic carnitine synthesis and uptake of carnitine (OCTN1) in the liver, irrespective of litter size. Carnitine 150-159 peroxisome proliferator activated receptor alpha Rattus norvegicus 110-119 19154956-6 2009 In conclusion, the present study demonstrates for the first time that lactation leads to a down-regulation of PPARalpha and genes involved in hepatic carnitine synthesis and uptake of carnitine (OCTN1) in the liver, irrespective of litter size. Carnitine 184-193 peroxisome proliferator activated receptor alpha Rattus norvegicus 110-119 18309235-1 2008 BACKGROUND: Recently, we have shown that activation of peroxisome proliferator-activated receptor (PPAR)-alpha by clofibrate leads to an upregulation of novel organic cation transporter (OCTN)-2, a carnitine transporter, and in turn increases the carnitine concentration in the liver of rats. Carnitine 198-207 peroxisome proliferator activated receptor alpha Rattus norvegicus 55-110 18620058-0 2008 Treatment with pharmacological peroxisome proliferator-activated receptor alpha agonist clofibrate increases intestinal carnitine absorption in rats. Carnitine 120-129 peroxisome proliferator activated receptor alpha Rattus norvegicus 31-79 18620058-2 2008 This strongly suggests that PPARalpha activation in response to clofibrate treatment improves the absorption of carnitine from the diet. Carnitine 112-121 peroxisome proliferator activated receptor alpha Rattus norvegicus 28-37 18520060-7 2008 In conclusion, our results indicate that the nuclear receptor PPARalpha directly up-regulates the expression of rOctn2 and increases the hepatic uptake of carnitine via rOctn2. Carnitine 155-164 peroxisome proliferator activated receptor alpha Rattus norvegicus 62-71 23150726-0 2012 Regulation of Genes Involved in Carnitine Homeostasis by PPARalpha across Different Species (Rat, Mouse, Pig, Cattle, Chicken, and Human). Carnitine 32-41 peroxisome proliferator activated receptor alpha Rattus norvegicus 57-66 17644405-1 2007 Activation of PPARalpha by clofibrate has recently been shown to cause upregulation of carnitine transporter organic cation transporter (OCTN) 2 and elevated carnitine concentrations in rat liver. Carnitine 87-96 peroxisome proliferator activated receptor alpha Rattus norvegicus 14-23 23150726-4 2012 However, despite demonstrating a well-conserved role of PPARalpha as a key regulator of carnitine homeostasis in general, our comprehensive analysis shows that this assumption particularly applies to the regulation by PPARalpha of carnitine uptake which is obviously highly conserved across species, whereas regulation by PPARalpha of carnitine biosynthesis appears less well conserved across species. Carnitine 88-97 peroxisome proliferator activated receptor alpha Rattus norvegicus 218-227 23150726-4 2012 However, despite demonstrating a well-conserved role of PPARalpha as a key regulator of carnitine homeostasis in general, our comprehensive analysis shows that this assumption particularly applies to the regulation by PPARalpha of carnitine uptake which is obviously highly conserved across species, whereas regulation by PPARalpha of carnitine biosynthesis appears less well conserved across species. Carnitine 88-97 peroxisome proliferator activated receptor alpha Rattus norvegicus 218-227 23150726-4 2012 However, despite demonstrating a well-conserved role of PPARalpha as a key regulator of carnitine homeostasis in general, our comprehensive analysis shows that this assumption particularly applies to the regulation by PPARalpha of carnitine uptake which is obviously highly conserved across species, whereas regulation by PPARalpha of carnitine biosynthesis appears less well conserved across species. Carnitine 231-240 peroxisome proliferator activated receptor alpha Rattus norvegicus 56-65 23150726-4 2012 However, despite demonstrating a well-conserved role of PPARalpha as a key regulator of carnitine homeostasis in general, our comprehensive analysis shows that this assumption particularly applies to the regulation by PPARalpha of carnitine uptake which is obviously highly conserved across species, whereas regulation by PPARalpha of carnitine biosynthesis appears less well conserved across species. Carnitine 231-240 peroxisome proliferator activated receptor alpha Rattus norvegicus 218-227 23150726-4 2012 However, despite demonstrating a well-conserved role of PPARalpha as a key regulator of carnitine homeostasis in general, our comprehensive analysis shows that this assumption particularly applies to the regulation by PPARalpha of carnitine uptake which is obviously highly conserved across species, whereas regulation by PPARalpha of carnitine biosynthesis appears less well conserved across species. Carnitine 231-240 peroxisome proliferator activated receptor alpha Rattus norvegicus 218-227 17524183-1 2007 It has been shown that treatment of rats with clofibrate, a synthetic agonist of PPARalpha, increases mRNA concentration of organic cation transporters (OCTN)-1 and -2 and concentration of carnitine in the liver. Carnitine 189-198 peroxisome proliferator activated receptor alpha Rattus norvegicus 81-90 17524183-8 2007 The present study supports the hypothesis that nutrients acting as PPARalpha agonists influence whole-body carnitine homeostasis. Carnitine 107-116 peroxisome proliferator activated receptor alpha Rattus norvegicus 67-76 17011512-3 2006 In this study, we observed for the first time that treatment of rats with the peroxisome proliferator activated receptor (PPAR)-alpha agonist clofibrate increases hepatic mRNA concentrations of organic cation transporters (OCTNs)-1 and -2 which act as transporters of carnitine into the cell. Carnitine 268-277 peroxisome proliferator activated receptor alpha Rattus norvegicus 122-133 17011512-6 2006 We conclude that PPARalpha agonists increase carnitine concentrations in livers of rats and cells by an increased uptake of carnitine into the cell but not by an increased carnitine biosynthesis. Carnitine 45-54 peroxisome proliferator activated receptor alpha Rattus norvegicus 17-26 17011512-6 2006 We conclude that PPARalpha agonists increase carnitine concentrations in livers of rats and cells by an increased uptake of carnitine into the cell but not by an increased carnitine biosynthesis. Carnitine 124-133 peroxisome proliferator activated receptor alpha Rattus norvegicus 17-26 17011512-6 2006 We conclude that PPARalpha agonists increase carnitine concentrations in livers of rats and cells by an increased uptake of carnitine into the cell but not by an increased carnitine biosynthesis. Carnitine 124-133 peroxisome proliferator activated receptor alpha Rattus norvegicus 17-26 23150726-1 2012 Recent studies in rodents convincingly demonstrated that PPARalpha is a key regulator of genes involved in carnitine homeostasis, which serves as a reasonable explanation for the phenomenon that energy deprivation and fibrate treatment, both of which cause activation of hepatic PPARalpha, causes a strong increase of hepatic carnitine concentration in rats. Carnitine 107-116 peroxisome proliferator activated receptor alpha Rattus norvegicus 57-66 23150726-1 2012 Recent studies in rodents convincingly demonstrated that PPARalpha is a key regulator of genes involved in carnitine homeostasis, which serves as a reasonable explanation for the phenomenon that energy deprivation and fibrate treatment, both of which cause activation of hepatic PPARalpha, causes a strong increase of hepatic carnitine concentration in rats. Carnitine 107-116 peroxisome proliferator activated receptor alpha Rattus norvegicus 279-288 23150726-4 2012 However, despite demonstrating a well-conserved role of PPARalpha as a key regulator of carnitine homeostasis in general, our comprehensive analysis shows that this assumption particularly applies to the regulation by PPARalpha of carnitine uptake which is obviously highly conserved across species, whereas regulation by PPARalpha of carnitine biosynthesis appears less well conserved across species. Carnitine 88-97 peroxisome proliferator activated receptor alpha Rattus norvegicus 56-65 35567992-5 2022 RESULTS: Based on the construction of the rhein-target-metabolic enzyme-metabolite network, we found that rhein played an antifibrotic role through the PPAR-alpha-CPT1A-l-palmitoyl-carnitine axis. Carnitine 181-190 peroxisome proliferator activated receptor alpha Rattus norvegicus 152-162 31308847-6 2019 Treatment with the PPARalpha agonist was associated with higher liver mass relative to body weight (liver index), lower plasma, and hepatic total cholesterol, as well as lower plasma carnitine and acylcarnitines, compared with control. Carnitine 183-192 peroxisome proliferator activated receptor alpha Rattus norvegicus 19-28